Pharma BD Deal Intelligence
Regeneron and Alnylam ink $1 billion eye and central nervous system R&D deal to advance RNAi therapeutics across 30 targets
Regeneron to invest $800 million in Alnylam for RNAi therapeutics collaboration targeting eye and CNS diseases with equity stake
ALN-APP (mivelsiran) Phase 1 enrolling with potent, durable APPbeta reduction; ALN-HTT02 Huntington's disease Phase 1b ongoing, developed in partnership with…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Regeneron and Alnylam entered a broad strategic collaboration to discover, develop, and commercialize RNAi therapeutics for eye and CNS diseases. Regeneron made a $400 million equity investment in Alnylam and the deal included development milestones and profit-sharing arrangements.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. (this deal) | 2019 | $1.0B | 77 |
| Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. | 2026 | $4.0B | 62 |
| Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) | 2022 | $1.1B | — |
| Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. | 2025 | $256M | — |
| Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. | 2026 | $2.3B | — |
| Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited | 2026 | $2.1B | — |
| Regeneron Pharmaceuticals, Inc. / Tessera Therapeutics, Inc. | 2025 | $275M | — |
← Browse all deals · How we score deals
More: 2019 deals · Regeneron Pharmaceuticals, Inc. deals · Neurology deals